{
  "trial_id": "NCT02700022",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "\u226518 y/o",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "ECOG PS \u22642",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Disease - Histologically or cytologically documented newly diagnosed (stages II, III or IV) Myc-positive DLBCL, transformed follicular lymphoma, or high-grade unclassifiable with features intermediate between DLBCL and Burkitt lymphoma",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Myc Positive lymphoma is defined by: Positive for Myc gene rearrangement by fluorescence in-situ hybridization (FISH) involving various breakpoints (e.g. 8-14, 8-22 and 2-8) AND concurrent gene rearrangements in bcl-2 and/or bcl-6 by FISH OR Myc and Bcl-2 overexpression defined by > 40% Myc and > 70% Bcl-2 expression by IHC.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Positive for CD20 via immunophenotyping",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e. R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Measurable disease as assessed by 2 dimensional measurements by CT (\u2265 1.5 cm).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Adequate organ function as demonstrated by: Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by:",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Hemoglobin \u2265 8 g/dL",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "CNS involvement of DLBCL",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Major surgery within 4 weeks prior to entry",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent ; NOTE: Concurrent intrathecal chemotherapy for CNS prophylaxis allowed per institutional standards",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT02700022",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_test10_top50"
  }
}